<DOC>
	<DOCNO>NCT00395915</DOCNO>
	<brief_summary>The principal clinical question answer CHAT ( Clozapine Haloperidol Aripiprazole Trial ) relative efficacy tolerability combination treatment clozapine plus aripiprazole compare combination treatment clozapine plus haloperidol patient incomplete response treatment clozapine appropriate period time .</brief_summary>
	<brief_title>Randomized Evaluation Effectiveness Clozapine Aripiprazole Versus Clozapine Haloperidol Treatment Schizophrenia</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Haloperidol</mesh_term>
	<mesh_term>Haloperidol decanoate</mesh_term>
	<mesh_term>Clozapine</mesh_term>
	<mesh_term>Aripiprazole</mesh_term>
	<criteria>1 . Current treatment clozapine primary indication schizophrenia ( clinical diagnosis , guide DSMIV criterion ) . 2 . Treatment clozapine least six month stable dose 400 mg per day , unless size dose limited sideeffects . 3 . Unsatisfactory benefit clozapine treatment , indicate presence positive symptom ( delusion , hallucination , abnormal behaviour , clinical diagnosis ) 4 . Age 18 . 5 . Agreement investigator patient enter study . 6 . The patient normally resident Italy . 7 . It consider clinically reasonable try combination treatment clozapine aripiprazole clozapine haloperidol . 8 . Uncertainty trial treatment would best participant . 9 . No medical disorder condition contraindicate either investigational drug . 10 . Agreement investigator patient discontinue antipsychotic drug clozapine ( include longacting antipsychotic drug ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2009</verification_date>
	<keyword>schizophrenia</keyword>
	<keyword>antipsychotic</keyword>
	<keyword>treatment non response</keyword>
	<keyword>pragmatic trial</keyword>
</DOC>